Pfizer has been in the spotlight a lot these days after the company made the covid vaccines. Now, the firm is addressing its viable treatment for the terrible disease. Check out the latest reports about all this and make sure to stay tuned for more coronavirus-related news.
Pfizer addresses experimental pill anti covid
CBS News reports that Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90%. The drugmaker joined the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.
For now, the covid treatments used in the U.S. require an IV or injection.
You are probably aware of the fact that competitor Merck’s pill is already under review at the FDA after showing strong initial results, and on Thursday the United Kingdom became the first country to approve it.
The same online publication mentioned above notes that “Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results.”
It’s also important to note the fact that after Pfizer applies, the FDA could make a decision within weeks or months.
Pfizer CEO talks vaccines and treatments
Pfizer CEO Albert Bourla told CNBC the following:
“The fact that we have a treatment is not at all a reason not to take the vaccine, in fact we should take the vaccine. Some unfortunately will get the disease.”
He continued and said this:
The antiviral pills are “for people that already they got the disease. This is for sick people, the goal here is to prevent people from getting sick.”
That’s where Covid booster shots come in, he added.
“Boosters are needed because without them we will never get rid of this vicious cycle of the disease.”
Stay tuned for more news.
